$VSTM News

RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14

Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers - Slideshow

HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target

BTIG Reiterates Buy on Verastem, Maintains $18 Price Target

Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript

Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clinical Activity Including Favorable Safety Profile; Broad Anti-Tumor Activity Observed

Verastem: 'Buy' Positive RAMP-205 Data And Extensive VS-7375 Registration Program

Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer

Verastem Announces Updated Safety, Efficacy Results From RAMP 205 Evaluating Avutometinib Plus Defactinib In Combination With Gemcitabine And Nab-Paclitaxel In First-Line Metastatic Pancreatic Cancer

Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal Carcinoma

Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Program And Updated Preliminary Data From Phase 1/2 TARGET-D 101 Dose Escalation And Dose Expansion Trial

Verastem Obtains U.S. FDA Fast Track Designation For VS-7375; Phase 1 TARGET-D 101 Dose Escalation, Dose Expansion, And Combination Clinical Trial Ongoing With Early Data Updates Expected In The First Half Of 2026 And More Mature Data Expected In The Second Half Of 2026

Mizuho Maintains Outperform on Verastem, Lowers Price Target to $14

Verastem Q1 Earnings Call Highlights

Verastem, Inc. 2026 Q1 - Results - Earnings Call Presentation

Verastem (VSTM) Q1 2026 Earnings Transcript

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

BTIG Maintains Buy on Verastem, Lowers Price Target to $18

Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript

Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss